{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:27:38Z","timestamp":1778858858946,"version":"3.51.4"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T00:00:00Z","timestamp":1458777600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0151800","type":"journal-article","created":{"date-parts":[[2016,3,24]],"date-time":"2016-03-24T17:55:23Z","timestamp":1458842123000},"page":"e0151800","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Successful Phenotype Improvement following Gene Therapy for Severe Hemophilia A in Privately Owned Dogs"],"prefix":"10.1371","volume":"11","author":[{"given":"Mary Beth","family":"Callan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark E.","family":"Haskins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine A.","family":"High","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valder R.","family":"Arruda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,3,24]]},"reference":[{"key":"ref1","article-title":"Harrison's Principles of Internal Medicine","author":"V Arruda","year":"2015"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1046\/j.1365-2141.1999.01463.x","article-title":"Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized","volume":"105","author":"J Astermark","year":"1999","journal-title":"Br J Haematol"},{"issue":"6","key":"ref3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"MJ Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"13","key":"ref4","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"J Oldenburg","year":"2015","journal-title":"Blood"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0037-1612943","article-title":"The North American Immune Tolerance Registry: practices, outcomes, outcome predictors","volume":"87","author":"DM DiMichele","year":"2002","journal-title":"Thromb Haemost"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"CR Hay","year":"2012","journal-title":"Blood"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"SC Gouw","year":"2007","journal-title":"Blood"},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"J Wight","year":"2003","journal-title":"Haemophilia"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2516.2000.00417.x","article-title":"Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism","volume":"6","author":"BL Evatt","year":"2000","journal-title":"Haemophilia"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"CS Manno","year":"2006","journal-title":"Nat Med"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1182\/blood.V99.8.2670","article-title":"Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy","volume":"99","author":"JD Mount","year":"2002","journal-title":"Blood"},{"issue":"21","key":"ref12","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"AC Nathwani","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ilar.50.2.144","article-title":"Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency","volume":"50","author":"TC Nichols","year":"2009","journal-title":"ILAR Journal"},{"issue":"26","key":"ref14","doi-asserted-by":"crossref","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","article-title":"Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy","volume":"116","author":"JD Finn","year":"2010","journal-title":"Blood"},{"issue":"17","key":"ref15","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"J McIntosh","year":"2013","journal-title":"Blood"},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"DE Sabatino","year":"2011","journal-title":"Mol Ther"},{"issue":"21","key":"ref17","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2012-10-464164","article-title":"Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype","volume":"121","author":"JI Siner","year":"2013","journal-title":"Blood"},{"issue":"20","key":"ref18","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood-2013-10-534032","article-title":"Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy","volume":"123","author":"N Nair","year":"2014","journal-title":"Blood"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V63.2.451.451","article-title":"Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency)","volume":"63","author":"AR Giles","year":"1984","journal-title":"Blood"},{"issue":"20","key":"ref20","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1182\/blood-2009-05-220327","article-title":"Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model","volume":"114","author":"DE Sabatino","year":"2009","journal-title":"Blood"},{"issue":"194","key":"ref21","doi-asserted-by":"crossref","first-page":"194ra192","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"F Mingozzi","year":"2013","journal-title":"Sci Transl Med"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"H Jiang","year":"2006","journal-title":"Blood"},{"issue":"11","key":"ref23","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1089\/hum.2011.031","article-title":"Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors","volume":"22","author":"L Wang","year":"2011","journal-title":"Hum Gene Ther"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","article-title":"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice","volume":"125","author":"JM Crudele","year":"2015","journal-title":"Blood"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1111\/j.1538-7836.2010.03978.x","article-title":"WAG-F8(m1Ycb) rats harboring a factor VIII gene mutation provide a new animal model for hemophilia A","volume":"8","author":"CJ Booth","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1538-7836.2009.03697.x","article-title":"Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A","volume":"8","author":"CD Porada","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"Suppl 1","key":"ref27","article-title":"and Model Systems for Hemophilia A Gene Therapy","author":"J Mao","year":"2013","journal-title":"J Genet Syndr Gene Ther"},{"issue":"Suppl 4","key":"ref28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/hae.12409","article-title":"Genetic testing in bleeding disorders","volume":"20","author":"C de Brasi","year":"2014","journal-title":"Haemophilia"},{"issue":"11","key":"ref29","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/j.1538-7836.2008.03125.x","article-title":"Detection of large duplications within the factor VIII gene by MLPA","volume":"6","author":"S Rost","year":"2008","journal-title":"J Thromb Haemost"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1055\/s-0037-1613063","article-title":"Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe canine hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia","volume":"87","author":"C Hough","year":"2002","journal-title":"Thromb Haemost"},{"issue":"20","key":"ref31","doi-asserted-by":"crossref","first-page":"12991","DOI":"10.1073\/pnas.192219599","article-title":"The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion","volume":"99","author":"JN Lozier","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/humc.2014.153","article-title":"Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs","volume":"26","author":"TC Nichols","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"4","key":"ref33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/blood-2008-10-181479","article-title":"Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy","volume":"113","author":"GP Niemeyer","year":"2009","journal-title":"Blood"},{"issue":"4","key":"ref34","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/hum.2011.106","article-title":"Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia","volume":"23","author":"A Demaster","year":"2012","journal-title":"Hum Gene Ther"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/gt.2011.90","article-title":"Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia","volume":"19","author":"C Li","year":"2012","journal-title":"Gene Ther"},{"issue":"6","key":"ref36","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"S Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"R Calcedo","year":"2013","journal-title":"Front Immunol"},{"issue":"85","key":"ref38","first-page":"379","article-title":"Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions","volume":"15","author":"E Masat","year":"2013","journal-title":"Discov Med"},{"issue":"4","key":"ref39","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue","volume":"20","author":"F Mingozzi","year":"2013","journal-title":"Gene Ther"},{"issue":"7488","key":"ref40","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"L Lisowski","year":"2014","journal-title":"Nature"},{"issue":"5","key":"ref41","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"AC Nathwani","year":"2011","journal-title":"Mol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0151800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T19:27:08Z","timestamp":1600370828000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0151800"}},"subtitle":[],"editor":[{"given":"Knut","family":"Stieger","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,24]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0151800","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,24]]}}}